Cardiac sodium channelopathies
- PMID: 20091048
- PMCID: PMC2883928
- DOI: 10.1007/s00424-009-0761-0
Cardiac sodium channelopathies
Abstract
Cardiac sodium channel are protein complexes that are expressed in the sarcolemma of cardiomyocytes to carry a large inward depolarizing current (INa) during phase 0 of the cardiac action potential. The importance of INa for normal cardiac electrical activity is reflected by the high incidence of arrhythmias in cardiac sodium channelopathies, i.e., arrhythmogenic diseases in patients with mutations in SCN5A, the gene responsible for the pore-forming ion-conducting alpha-subunit, or in genes that encode the ancillary beta-subunits or regulatory proteins of the cardiac sodium channel. While clinical and genetic studies have laid the foundation for our understanding of cardiac sodium channelopathies by establishing links between arrhythmogenic diseases and mutations in genes that encode various subunits of the cardiac sodium channel, biophysical studies (particularly in heterologous expression systems and transgenic mouse models) have provided insights into the mechanisms by which INa dysfunction causes disease in such channelopathies. It is now recognized that mutations that increase INa delay cardiac repolarization, prolong action potential duration, and cause long QT syndrome, while mutations that reduce INa decrease cardiac excitability, reduce electrical conduction velocity, and induce Brugada syndrome, progressive cardiac conduction disease, sick sinus syndrome, or combinations thereof. Recently, mutation-induced INa dysfunction was also linked to dilated cardiomyopathy, atrial fibrillation, and sudden infant death syndrome. This review describes the structure and function of the cardiac sodium channel and its various subunits, summarizes major cardiac sodium channelopathies and the current knowledge concerning their genetic background and underlying molecular mechanisms, and discusses recent advances in the discovery of mutation-specific therapies in the management of these channelopathies.
Figures









Similar articles
-
Genetic Na+ channelopathies and sinus node dysfunction.Prog Biophys Mol Biol. 2008 Oct-Nov;98(2-3):171-8. doi: 10.1016/j.pbiomolbio.2008.10.003. Epub 2008 Nov 5. Prog Biophys Mol Biol. 2008. PMID: 19027778 Review.
-
Cardiac Arrhythmias Related to Sodium Channel Dysfunction.Handb Exp Pharmacol. 2018;246:331-354. doi: 10.1007/164_2017_43. Handb Exp Pharmacol. 2018. PMID: 28965168 Review.
-
Cardiac sodium channelopathy associated with SCN5A mutations: electrophysiological, molecular and genetic aspects.J Physiol. 2013 Sep 1;591(17):4099-116. doi: 10.1113/jphysiol.2013.256461. Epub 2013 Jul 1. J Physiol. 2013. PMID: 23818691 Free PMC article. Review.
-
Clinical Spectrum of SCN5A Mutations: Long QT Syndrome, Brugada Syndrome, and Cardiomyopathy.JACC Clin Electrophysiol. 2018 May;4(5):569-579. doi: 10.1016/j.jacep.2018.03.006. Epub 2018 May 2. JACC Clin Electrophysiol. 2018. PMID: 29798782 Review.
-
[Cardiac sodium channelopathy from bench to bedside].Zhonghua Er Ke Za Zhi. 2013 Nov;51(11):874-7. Zhonghua Er Ke Za Zhi. 2013. PMID: 24484568 Review. Chinese. No abstract available.
Cited by
-
Biophysics, pathophysiology, and pharmacology of ion channel gating pores.Front Pharmacol. 2014 Apr 3;5:53. doi: 10.3389/fphar.2014.00053. eCollection 2014. Front Pharmacol. 2014. PMID: 24772081 Free PMC article. Review.
-
A novel NaV1.5 voltage sensor mutation associated with severe atrial and ventricular arrhythmias.J Mol Cell Cardiol. 2016 Mar;92:52-62. doi: 10.1016/j.yjmcc.2016.01.014. Epub 2016 Jan 19. J Mol Cell Cardiol. 2016. PMID: 26801742 Free PMC article.
-
A Heart Failure-Associated SCN5A Splice Variant Leads to a Reduction in Sodium Current Through Coupled-Gating With the Wild-Type Channel.Front Physiol. 2021 Mar 22;12:661429. doi: 10.3389/fphys.2021.661429. eCollection 2021. Front Physiol. 2021. PMID: 33828490 Free PMC article.
-
Cellular hyper-excitability caused by mutations that alter the activation process of voltage-gated sodium channels.Front Physiol. 2015 Feb 17;6:45. doi: 10.3389/fphys.2015.00045. eCollection 2015. Front Physiol. 2015. PMID: 25741286 Free PMC article. Review.
-
Mexiletine differentially restores the trafficking defects caused by two brugada syndrome mutations.Front Pharmacol. 2012 Apr 20;3:62. doi: 10.3389/fphar.2012.00062. eCollection 2012. Front Pharmacol. 2012. PMID: 22529811 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous